Neuroprotective Therapy with Citicoline (Ceraxon) in Patients with Ischemic Stroke

The dynamics of neurological symptoms were assessed using the Scandinavia Stroke Scale and functional disease outcomes with the Barthel index and modified Rankin scale in 89 patients during the acute period of ischemic stroke of moderate severity, whose treatment included citicoline (Ceraxon) i.v. a...

Full description

Saved in:
Bibliographic Details
Published in:Neuroscience and behavioral physiology 2013-07, Vol.43 (6), p.706-711
Main Authors: Martynov, M. Yu, Boiko, A. N., Kamchatnov, P. R., Kabanov, A. A., Yasamanova, A. N., Shchukin, I. A., Kolesnikova, T. I., Chubykin, V. I., Glukhareva, A. P., Gusev, E. I.
Format: Article
Language:English
Subjects:
Behavioral Sciences
Biomedical and Life Sciences
Biomedicine
Consciousness
Convulsions & seizures
Epilepsy
Illnesses
Ischemia
Neurobiology
Neurons
Neurosciences
Stroke
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The dynamics of neurological symptoms were assessed using the Scandinavia Stroke Scale and functional disease outcomes with the Barthel index and modified Rankin scale in 89 patients during the acute period of ischemic stroke of moderate severity, whose treatment included citicoline (Ceraxon) i.v. and p.o. The results were compared with those from a reference group (52 patients) selected in terms of clinical and demographic parameters, who received similar treatment without citicoline. By discharge from hospital (days 21–24 of illness), there was significantly ( p < 0.05) greater recovery in the study group. The efficacy of citicoline was significantly ( p < 0.05) greater in patients aged less than 70 years and when citicoline was given in the first hours of illness.
ISSN:0097-0549
1573-899X
DOI:10.1007/s11055-013-9797-x